Variability Among Next-Generation Sequencing Panels for Early-Life Epilepsies
Epilepsy genetics is an emerging field with increasing therapeutic implications resulting from genetic findings.
1 Despite an overall enthusiasm for precision medicine in epilepsy and other disciplines, there remains no consensus on the approach to genetic testing. 2 A recent study by Berg et al 3 demonstrated a relatively similar diagnostic yield of epilepsy next-generation sequencing (NGS) gene panels compared with whole-exome sequencing (27% vs 33%). Although the utility of NGS panels are consistently demonstrated, 3, 4 to our knowledge, no study has systematically evaluated the variability in genes tested among clinically available NGS panels. We compared the potential diagnostic yield of commercially available NGS epilepsy panels to detect the genetic findings identified in a recently published cohort of early-life epilepsy. accounted for multiple patients. The comprehensive epilepsy panels included 40% to 65% of genes and 61% to 79% of the pathogenic variants in the cohort.
Discussion | Epilepsy genetics is an evolving field with an expanding number of causative genes. Next-generation sequencing panels have a high yield for genetically heterogeneous conditions, such as epilepsy. 4 However, we found inconsistency in the genes offered on epilepsy panels, which translates to variability in the diagnostic yield. Only the largest comprehensive epilepsy panels had improved detection of genetic findings compared with the early-life epilepsy panels. The yield of a rapid 16-gene panel was almost equivalent to that of a 67-gene panel. Thus, for known epilepsy genes, a bigger panel is not inherently better.
In our analysis, the early-life epilepsy panels would have missed between 41% and 86% of the patients with pathogenic variants in confirmed epilepsy genes. Epilepsy NGS panels often do not include recently identified epilepsy genes or genes associated with a syndrome in which epilepsy is not a core feature. Coverage and detection of exon-level deletions or duplications can vary across panels. Our study underscores the importance of a clinician's diagnostic suspicion to select the appropriate test for the appropriate patient. Despite the limitations, an appropriately chosen NGS panel remains an important step in the diagnostic workup for epilepsy.
This study highlights the variability across NGS panels and leads to the following recommendations for researchers, diagnostic laboratories, and clinicians. Research using NGS panels may not be generalizable, and future research should at least report the genes that were tested. Diagnostic laboratories should use published cohorts and current literature to continually update and evaluate their panels. Clinicians must understand that NGS panels are not created equally and may consider discussing test selection with a content expert in epilepsy genetics, such as a consultant in genetics, neurogenetics, or genetic counseling.
Prevalence of Dietary Supplement Use in US Children and Adolescents, 2003-2014
Dietary supplements are often implicated in preventable adverse drug events in children and adolescents, 1 yet current data on their use in this population are lacking. We used nationally representative data from the National Health and Nutrition Examination Surveys (NHANES) to estimate the prevalence of dietary supplement use, including the use of both nutritional products and alternative medicines, among children and adolescents in the United States.
Methods | We reviewed 6 recent 2-year cycles (2003-2004 through 2013-2014) of NHANES data and restricted our sample to children and adolescents (aged 0-19 years) who responded to the dietary supplement questionnaire. A parent or caregiver provided information for survey participants who were younger than 16 years and for those who could not answer the questionnaire for themselves. Dietary supplement data were collected during the household interview. Participants were asked whether they had "used or taken any vitamins, minerals, herbals, or other dietary supplements in the past 30 days." Those participants who answered yes were asked to show the interviewer the containers for all the dietary supplements used.
2 Nutritional products were defined as all products that primarily contain vitamins or minerals. Alternative medicines were defined as herbal, nonvitamin, or nonmineral supplements. Each supplement was further classified by its primary use (eg, bodybuilding) or its primary ingredient (eg, ω-3 fatty acids). (Figure, A) . While the use of nutritional products did not change between 2003 to 2004 and 2013 to 2014, the use of alternative medicines nearly doubled (3.7%; 95% CI, 2.8%-4.7% vs 6.7%; 95% CI, 4.8%-8.3%; P < .001). The higher rate in the use of alternative medicines was primarily because of increases in the use of ω-3 fatty acid supplements (0.4%; 95% CI, 0.2%-0.9% vs 2.3%; 95% CI, 1.4%-3.5%; P < .001) and melatonin supplements (0% vs 0.9%; 95% CI, 0.5%-1.7%; P < .001). In both boys and girls, the use of any dietary supplements, specifically nutritional products, was lowest and of alternative medicines was highest during adolescence (aged 13-19 years) (Figure, B) . From 2013 to 2014, multivitamins were the most commonly used dietary supplement (25.1%; 95% CI, 22.3%-28.1%) followed by supplements for immunity (3.8%; 95% CI, 2.8%-5.2%), ω-3 fatty acids (2.3%; 95% CI, 1.4%-3.6%), and sleep aids (1.1%; 95% CI, 0.6%-1.9%) (Table) . Significant sex differences were only observed during adolescence: iron, calcium, multivitamins, and single vitamins, particularly vitamin B products, were more commonly used among adolescent girls, whereas adolescent boys were more likely to use ω-3 fatty acid supplements and bodybuilding supplements.
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